Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13751142 | 0.95 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1KMT2AATMRAB9A | |
| SCHEMBL26618041 | 0.87 | CHRM2 (0.39) | — | |
| SCHEMBL13751271 | 0.86 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1KMT2AATMRAB9A | |
| SCHEMBL27009994 | 0.82 | L3MBTL1 (0.33) | L3MBTL1KMT2A | |
| SCHEMBL8442604 | 0.81 | LMNA (0.36) | KMT2A | |
| SCHEMBL19120709 | 0.81 | DRD2 (0.36) | ALDH1A1KMT2A | |
| SCHEMBL10942894 | 0.81 | LMNA (0.36) | KMT2A | |
| SCHEMBL28494816 | 0.81 | LMNA (0.36) | KMT2A | |
| SCHEMBL22318124 | 0.80 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL21583674 | 0.79 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197860-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197860-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | BRCA1, VHL, AADAC | ALDH1A1 782/4885L3MBTL1 3010/4885KMT2A 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.